AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00772057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
Study NCT00772057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets given two times daily.
Study NCT01676233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT01676233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine- new formulation (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT02185183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alequel
Description: Alequel
Study NCT00846157 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NKM injection
Description: NKCell about 100mg IV for 6times in each chemotherapy period.
Study NCT01216488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine
Description: 40 ml or 25 ml of Xylocaine injection
Study NCT01216488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: 40 ml or 25 ml of Xylocaine injection
Study NCT03674281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAP
Description: Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
Study NCT03674281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLC
Description: The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
Study NCT02301897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate
Description: Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Study NCT02301897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Study NCT01969734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zephyr endobronchial valve placement
Study NCT02965781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SADBE
Description: Topical solution
Study NCT02965781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Topical solution
Study NCT02965781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical solution
Study NCT02675400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyvanse
Description: Half of the participants (fathers) will be randomized to receive Vyvanse.
Study NCT02675400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Half of the fathers will receive behavioral parent training.
Study NCT02675400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: If Vyvanse is not well tolerated, methylphenidate can be prescribed.
Study NCT02179034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
Study NCT02179034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Menthol
Description: A low dose of menthol will be added to the tobacco flavor.
Study NCT02179034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose Menthol
Description: A low dose of menthol will be added to the tobacco flavor.
Study NCT02179034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Menthol
Description: A high dose of menthol will be added to the tobacco flavor.
Study NCT02179034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Menthol
Description: A high dose of menthol will be added to the tobacco flavor.
Study NCT01695603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent
Study NCT03150264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV-VG, PEEP5cmH₂O
Description: This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
Study NCT03150264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCV, PEEP5cmH₂O
Description: This is a traditional ventilation mode used in obese patients in the past.
Study NCT00666263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (human), 10%
Description: Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
Study NCT00666263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.25% human albumin solution (Placebo)
Description: Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
Study NCT03895034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD)
Description: Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
Study NCT02178020 — intervention group
Intervention type: DEVICE
Intervention: knee arthroplasty, standard polyethylene
Description: total knee replacement follow-up; clinical and radiographic; revision rate
Study NCT02178020 — intervention group
Intervention type: DEVICE
Intervention: knee arthroplasty, XLP polyethylene
Description: total knee arthroplasty with highly crosslinked polyethylene tibial liner
Study NCT04870060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Lozenges
Description: Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
Study NCT02695290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT05318885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Randomized Controlled Study
Description: For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
Study NCT04455399 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intravitreal injection guide (Malosa)
Description: A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
Study NCT04455399 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual Blade Eyelid Speculum
Description: A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
Study NCT02139748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant & ADM
Description: A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
Study NCT02139748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant & ADM
Description: A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
Study NCT02139748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant & ADM & bone xenograft
Description: A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
Study NCT04633980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixture 3,6% H2 in N2 (96.4%)
Description: Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
Study NCT00666094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: supervised endurance training. Three sessions per week in three months.
Study NCT00666094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: Supervised strength training. Three sessions per week in three months.
Study NCT00328393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45 mg 8 weeks
Study NCT00328393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00568659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: specific elastance
Description: The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
Study NCT00752817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proficiency-based virtual reality simulation training
Description: Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
Study NCT00752817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training under the current surgical training programme
Description: Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
Study NCT01603784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Exercise
Description: Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at \~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max.
Study NCT01603784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
Study NCT01603784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
Study NCT01603784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment.
Study NCT05295134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
Study NCT05295134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Candida cylindracea lipase (225,000 FIP lipase units per day)
Description: Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
Study NCT05295134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Candida cylindracea lipase (450,000 FIP lipase units per day)
Description: Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
Study NCT05295134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Candida cylindracea lipase (675,000 FIP lipase units per day)
Description: Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
Study NCT04235283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)
Description: The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
Study NCT04235283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary total knee replacement by traditional jig and minimally invasive technique
Description: The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
Study NCT02715258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: tablets containing 20 mg bexagliflozin
Study NCT02715258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets matching the appearance of bexagliflozin tablets
Study NCT03439124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole medocaril
Description: Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.
Study NCT03439124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV standard-of-care cephalosporin
Description: Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed.
Study NCT02008019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day
Description: Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
Study NCT02008019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day
Description: Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
Study NCT03498651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification - Interpretation training
Description: Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
Study NCT03498651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
Study NCT03498651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online psychoeducation about anxiety
Description: Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Antiretroviral therapy
Study NCT01750307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental fatty acid supplementation
Description: 4 x capsules per day. Daily dose: 1584mg EFA
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Antiretroviral therapy
Study NCT03988452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Antiretroviral therapy
Study NCT02759341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manual for the Assessment and Documentation of Psychopathology (AMDP 8)
Study NCT01750307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: MCT oil softgel
Description: 4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
Study NCT04492631 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius DB-B5
Description: Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
Study NCT01406847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: High velocity low amplitude joint-biased intervention
Study NCT01406847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Mobilization
Description: Low velocity, large amplitude oscillating joint biased technique
Study NCT01406847 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Static Touch
Description: The investigators maintains hand contact with both hands over the lumbar area of the participant
Study NCT01972880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral
Study NCT01972880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP1941
Description: Oral